Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

C3G is estimated to affect around one person per million in the US, a small patient population, but is one of a series of ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Novartis AG's ( VTX:NOVN ) earnings announcement last week was disappointing for investors, despite the decent ...

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Novartis’ 2.7 billion euro ($2.9 billion) gamble on MorphoSys has hit turbulence. | Novartis’ 2.7 billion euro gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has ...

Novartis has received US Food and Drug Administration (FDA) accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid ...

Novartis forecasts full-year sales growth in ... and we completed our PSMAfore filing for Pluvicto in the US. With the momentum in our business and pipeline, we were able to once again upgrade ...